Thesis
momentum-code runs a deliberately simple idea: buy the top positive movers in a fixed large-cap universe, capped per position. The universe spans 24 names across tech, financials, healthcare, staples, and energy — AAPL, MSFT, NVDA, JPM, V, JNJ, XOM, and peers. There is no shorting and no market-timing overlay; the edge, if one exists, is pure cross-sectional momentum with position caps for diversification.
Backtest Performance
Over a 451-day window the strategy returned 19.76% (finalequity $11,976 on a $10,000 base), a 10.6% CAGR. Risk-adjusted, the picture is more modest: a Sharpe of 0.65 against a 20.48% maximum drawdown. Turnover of 92.74% is reasonable for a momentum book, and fees were negligible at $5 total. One figure to flag: the reported win rate is 0% across 5 trades — almost certainly an artifact of positions still being open (unrealized) rather than a string of realized losses, given the positive equity curve. It should not be read as a losing strategy, but it is a reminder that headline stats here rest on a very small sample.
Validation
The walk-forward analysis is where the nuance lives. Across four folds the strategy was positive in all four (+15.38%, +3.27%, +12.18%, +13.71%), with a healthy out-of-sample return of 13.71% and an OOS Sharpe of 1.93. Encouragingly, the weakest fold still stayed green.
Despite that, the validation gate failed. The deflated Sharpe ratio (DSR) came in at just 0.338, and with 6 trials behind the search, the probabilistic Sharpe of 0.811 was not enough to clear the bar. In plain terms: once you penalize for how many variants were tried, the evidence that this edge is real — rather than the best of several lucky draws — is thin. The gate is doing its job by refusing to rubber-stamp a promising-but-underpowered result.
Recent Live Activity
Here the story turns cautionary. The last executed trades were on 1 June 2026 — buys in XOM, NVDA, BAC, HON, and MSFT. Since then, every scheduled run has come up empty: six consecutive sessions (Aug 4–11) executed 0 trades, with 1–3 orders rejected each time. Cash has sat frozen at $608.79 and total value has drifted between roughly $10,682 and $10,828. Something — likely insufficient cash to meet position sizing, or a signal producing no fresh candidates — is preventing the book from acting.
Verdict
momentum-code has a clean, defensible thesis and a backtest that survived four walk-forward folds intact. Those are real strengths. But the failed DSR gate, the tiny trade count, and a week-long execution stall are genuine risks that outweigh the headline return. This is a strategy worth watching, not yet trusting — the immediate priority is diagnosing why live orders keep getting rejected before its statistics can be taken at face value.